Monday, December 23, 2024

Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc., developer of pioneering technologies to empower science, announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System.

“Element continues to expand its customer base, bringing high quality and cost-effective sequencing to researchers globally. Pairing Twist’s robust NGS workflows with Element’s AVITI technology will offer customers an economical and streamlined approach to next generation sequencing,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Because our tools are sequencer agnostic, we can extend the reach of our products with innovative companies like Element, and continue our commitment to empowering researchers to accelerate breakthroughs in scientific discovery by providing advanced tools.”

Also Read : Quantum-Si Expands Proteome Coverage and Increases Sequencing Output with New Enhancements to Its Next-Generation Protein Sequencing™ Platform

“We’ve laid out an ambitious product roadmap for 2024 to redefine what is possible on a sequencer and make it even easier for labs to produce the highest quality data at a low cost,” said Molly He, Ph.D., CEO and co-founder of Element Biosciences. “With the Twist for Element Exome Workflow, we are able to provide our customers with easy access to Twist’s Exome 2.0 panel and high performing library preparation and target enrichment reagents, saving them potential downstream sequencing costs by reducing per sample sequencing requirements.”

The Twist for Element Exome Workflow is a purpose-built solution for Element’s AVITI chemistry, alleviating the need for additional workflow steps for linear library conversion. The workflow will include Twist’s library preparation and target enrichment bundled with the Exome 2.0 and comprehensive spike-in. The Exome 2.0 delivers best-in-class sequencing due to its high uniformity and low off-target rate. It is designed to detect rare and inherited diseases, as well as germline cancers.

SOURCE : BusinessWire

Subscribe Now

    Hot Topics